Disease Domain | Count |
---|---|
Neoplasms | 6 |
Hemic and Lymphatic Diseases | 4 |
Immune System Diseases | 3 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Biosimilar | 3 |
Therapeutic vaccine | 2 |
Colony-stimulating factors | 2 |
Monoclonal antibody | 2 |
Fusion protein | 1 |
Target |
Mechanism GM3 inhibitors [+2] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CU |
First Approval Date23 Jun 2013 |
Target |
Mechanism EGF inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CU |
First Approval Date01 Jun 2008 |
Target |
Mechanism EGFR modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Sep 2024 |
Sponsor / Collaborator |
Start Date31 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Racotumomab ( GM3 ) | Non-Small Cell Lung Cancer More | Approved |
Recombinant human erythropoietin(Center of Molecular Immunology) ( EPO receptor ) | Anemia, Aplastic More | Approved |
Epidermal growth factor cancer vaccine(Center of Molecular Immunology) ( EGF ) | Non-Small Cell Lung Cancer More | Approved |
Filgrastim biosimilar(Center of Molecular Immunology) ( CSF-3R ) | Neutropenia More | Approved |
Rituximab biosimilar(Center of Molecular Immunology) ( CD20 ) | Non-Hodgkin Lymphoma More | Approved |